Seminars in Oncology
Volume 33 , Pages 36-43 , April 2006

The Role of Alemtuzumab in Nonmyeloablative Hematopoietic Transplantation

  • Sergio Giralt

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Sergio Giralt, MD, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA

References 

  1. Hale G , Slavin S , Goldman JM , et al.   Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? . Bone Marrow Transplant . 2002;30:797–804
  2. Slavin S , Nagler A , Naparstek E , et al.   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases . Blood . 1998;91:756–763
  3. Horowitz M , Gale R , Sondel P , et al.   Graft-versus-leukemia reactions after bone marrow transplantation . Blood . 1990;75:555–562
  4. Khouri IF , Keating M , Korbling M , et al.   Transplant-lite (induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies) . J Clin Oncol . 1998;16:2817–2824
  5. Maloney DG , Sandmaier BM , Mackinnon S , et al.   Non-myeloablative transplantation . Hematology (Am Soc Hematol Educ Program) . 2002;392–421
  6. McSweeney PA , Niederwieser D , Shizuru JA , et al.   Hematopoietic cell transplantation in older patients with hematologic malignancies (Replacing high-dose cytotoxic therapy with graft-versus-tumor effects) . Blood . 2001;97:3390–3400
  7. Giralt S , Thall PF , Khouri I , et al.   Melphalan and purine analog-containing preparative regimens (reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation) . Blood . 2001;97:631–637
  8. Hale G , Jacobs P , Wood L , et al.   CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells . Bone Marrow Transplant . 2000;26:69–76
  9. Chakrabarti S , MacDonald D , Hale G , et al.   T-cell depletion with Campath-1H “in the bag” for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival . Br J Haematol . 2003;121:109–118
  10. Morris EC , Rebello P , Thomson KJ , et al.   Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations (Relevance for early adoptive immunotherapy and infectious complications) . Blood . 2003;102:404–406
  11. Or R , Shapira MY , Resnick I , et al.   Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase . Blood . 2003;101:441–445
  12. Childs R , Clave E , Contentin N , et al.   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation (Full donor T-cell chimerism precedes alloimmune responses) . Blood . 1999;94:3234–3241
  13. Dreger P , Stilgenbauer S , Boettcher S , et al.   Long-term disease control of poor-risk chronic lymphocytic leukemia (CLL) by allogeneic stem cell transplantation with nonmyeloablative conditioning (NST) (Interim results of a prospective study) . 2005; Presented at the 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12
  14. Bensinger WI , Storb R . Allogeneic peripheral blood stem cell transplantation . Rev Clin Exp Hematol . 2001;5:67–86
  15. Cutler C , Giri S , Jeyapalan S , et al.   Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation (A meta-analysis) . J Clin Oncol . 2001;19:3685–3691
  16. Bensinger WI , Martin PJ , Storer B , et al.   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers . N Engl J Med . 2001;344:175–181
  17. Champlin RE , Schmitz N , Horowitz MM , et al.  IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT)   Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation . Blood . 2000;95:3702–3709
  18. Mavromatis B , Cheson BD . Monoclonal antibody therapy of chronic lymphocytic leukemia . J Clin Oncol . 2003;21:1874–1881
  19. Hale G , Rebello P , Brettman LR , et al.   Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration . Blood . 2004;104:948–955
  20. Hale G . Alemtuzumab in stem cell transplantation . Med Oncol . 2002;19(suppl):S33–S47
  21. Ratzinger G , Reagan JL , Heller G , et al.   Differential CD52 expression by distinct myeloid dendritic cell subsets (Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation) . Blood . 2003;101:1422–1429
  22. Chakrabarti S , Hale G , Waldmann H . Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation (Where do we go from here?) . Transplant Proc . 2004;36:1225–1227
  23. Khouri IF , Albitar M , Saliba RM , et al.   Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies (Decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics) . Bone Marrow Transplant . 2004;33:833–837
  24. Kottaridis PD , Milligan DW , Chopra R , et al.   In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation . Blood . 2000;96:2419–2425
  25. Perez-Simon JA , Kottaridis PD , Martino R , et al.   Nonmyeloablative transplantation with or without alemtuzumab (Comparison between 2 prospective studies in patients with lymphoproliferative disorders) . Blood . 2002;100:3121–3127
  26. Faulkner RD , Craddock C , Byrne JL , et al.   BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases (GVHD, toxicity, and survival in 65 patients) . Blood . 2004;103:428–434
  27. Chakraverty R , Robinson S , Peggs K , et al.   Excessive T-cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation . Bone Marrow Transplant . 2001;28:827–834
  28. Klangsinsirikul P , Carter GI , Byrne JL , et al.   Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution . Blood . 2002;99:2586–2591
  29. O’Brien SM , Kantarjian HM , Thomas DA , et al.   Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia . Cancer . 2003;98:2657–2663
  30. Dartigeas C , Degenne M , Senecal D , et al.   Efficacy and safety of alemtuzumab in patients with relapsed B-cell chronic lymphocytic leukemia after autologous stem cell transplantation . Blood . 2004;104:2509; (abstr)
  31. Montillo M , Tedeschi A , Miqueleiz S , et al.   Consolidation with alemtuzumab after a response to fludarabine in patients with CLL (Confirmation of the efficacy to purge residual disease) . Leuk Lymphoma . 2005;46(suppl 1):93; (abstr)
  32. Rawstron A , Villamor N , Ritgen M , et al.   International standardized approach to molecular and flow cytometric residual disease monitoring in CLL . Leuk Lymphoma . 2005;46(suppl 1):100; (abstr)
  33. Chakrabarti S , Mackinnon S , Chopra R , et al.   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation (Potential role of Campath-1H in delaying immune reconstitution) . Blood . 2002;99:4357–4363

PII: S0093-7754(06)00060-1

doi: 10.1053/j.seminoncol.2006.01.028

Seminars in Oncology
Volume 33 , Pages 36-43 , April 2006

Article Tools

* Image Usage & Resolution